Pfizer Inc (PFE)
Working capital turnover
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (ttm) | US$ in thousands | 63,627,000 | 60,113,000 | 55,643,000 | 55,094,000 | 58,497,000 | 68,538,000 | 77,944,000 | 92,952,000 | 100,331,000 | 99,879,000 | 101,335,000 | 92,570,000 | 81,491,000 | 69,337,000 | 57,374,000 | 50,198,000 | 47,644,000 | 48,648,000 | 49,197,000 | 50,660,000 |
| Total current assets | US$ in thousands | 50,358,000 | 43,223,000 | 37,825,000 | 42,415,000 | 43,333,000 | 74,012,000 | 73,347,000 | 50,078,000 | 51,259,000 | 70,403,000 | 67,466,000 | 54,420,000 | 59,693,000 | 57,900,000 | 48,814,000 | 39,533,000 | 35,067,000 | 47,739,000 | 46,424,000 | 34,738,000 |
| Total current liabilities | US$ in thousands | 42,995,000 | 43,211,000 | 43,819,000 | 40,497,000 | 47,794,000 | 31,136,000 | 34,647,000 | 36,562,000 | 42,138,000 | 44,314,000 | 47,410,000 | 39,268,000 | 42,671,000 | 41,803,000 | 35,664,000 | 26,652,000 | 25,920,000 | 34,154,000 | 32,723,000 | 33,890,000 |
| Working capital turnover | 8.64 | 5,009.42 | — | 28.72 | — | 1.60 | 2.01 | 6.88 | 11.00 | 3.83 | 5.05 | 6.11 | 4.79 | 4.31 | 4.36 | 3.90 | 5.21 | 3.58 | 3.59 | 59.74 |
December 31, 2024 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $63,627,000K ÷ ($50,358,000K – $42,995,000K)
= 8.64
Pfizer Inc's working capital turnover ratio provides insight into how effectively the company is utilizing its working capital to generate sales revenue. The trend analysis of the data shows some fluctuations over the reporting periods.
From March 31, 2020, to December 31, 2020, the working capital turnover ratio ranged between 3.59 and 5.21, indicating relatively stable performance during this period. There was a notable increase in the ratio to 6.11 by March 31, 2022, suggestive of improved efficiency in utilizing working capital to generate sales.
However, the ratio sharply declined to 2.01 by June 30, 2023, and further dropped to 1.60 by September 30, 2023, indicating a potential inefficiency in utilizing working capital during these periods.
Notably, there is missing data for December 31, 2023, and June 30, 2024, which could have provided further insights into the company's working capital turnover performance during these periods.
A significant spike is observed on September 30, 2024, where the ratio jumped to 5,009.42, which seems like an outlier and may be attributed to irregularities or inaccuracies in the data reported. This anomaly could distort the overall analysis of Pfizer Inc's working capital turnover if not properly investigated.
Overall, based on the available data, Pfizer Inc's working capital turnover ratio has shown variability over time, indicating fluctuations in the company's efficiency in utilizing its working capital to support sales operations, thus warranting further examination and scrutiny.
Peer comparison
Dec 31, 2024